Bruck Claudine
Known title: DirectorCIK: 0001733680
Bruck Claudine's purchase track record
Bruck Claudine has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/11/2021 | ANVS | $5K | -38.8% | -56.6% | +1.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ANVS | ▲ Buy | Option Exercise | 7,142 | $1000 | 9/10/2025 | View on chart |
| ANVS | ▲ Buy | Grant | 1,000 | $6K | 11/20/2023 | View on chart |
| ANVS | ▲ Buy | Grant | 500 | $6K | 4/7/2023 | View on chart |
| ANVS | ▲ Buy | Open Market | 181 | $5K | 10/11/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Annovis Bio Partners with Weave Bio for Alzheimer's NDA
Annovis Bio has announced a partnership with Weave Bio to use an AI regulatory platform. This collaboration is aimed at preparing the New Drug Application for buntanetap, a treatment for Alzheimer’s disease. The move supports the company's efforts to advance its lead candidate through the regulatory process.
Annovis Bio Partners with Weave Bio for Alzheimer's NDA. Annovis Bio has announced a partnership with Weave Bio to use an AI regulatory platform. This collaboration is aimed at preparing the New Drug Application for buntanetap, a treatment for Alzheimer’s disease. The move supports the company's efforts to advance its lead candidate through the regulatory process.